Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
Talazoparib significantly improved progression-free survival and objective response rate compared with physician's choice chemotherapy in patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer. Patient-reported quality of life improved with talazoparib and worsened with chemotherapy. Overall survival did not reach significance at interim analysis, likely confounded by subsequent PARP inhibitor use in the control arm.
Key Result: PFS (BICR) — 8.6 vs 5.6 months, HR 0.54 (95% CI 0.41–0.71; P<0.001)
Safety Signal: Grade 3–4 hematologic AEs in 55% (primarily anemia); dose modification required in 66% of patients. Nonhematologic grade 3 AEs lower than chemotherapy.
✅ Patient Eligibility
Must Have:
- Germline BRCA1 or BRCA2 mutation (deleterious/suspected deleterious)
- HER2-negative breast cancer
- Locally advanced (not amenable to curative therapy) or metastatic
- Prior taxane and/or anthracycline (unless contraindicated)
- ≤3 prior cytotoxic regimens for advanced disease
Cannot Have:
- HER2-positive disease
- No confirmed germline BRCA mutation
💊 Dosing Quick Guide
Experimental Regimen
Talazoparib: 1 mg PO once daily, continuously Cycle: Continuous (no defined cycle length) Duration: Until progression or unacceptable toxicity
Control Regimen
Physician's choice: Capecitabine (44%), eribulin (40%), gemcitabine (10%), or vinorelbine (7%) in 21-day cycles
Key Dose Modifications [2]
Per FDA prescribing information - Dose reduction levels: 1 mg → 0.75 mg → 0.5 mg once daily - Hold for grade 3–4 hematologic toxicity; resume at reduced dose when recovered - Monitor CBC monthly and as clinically indicated
Mechanism: Talazoparib is a PARP1/2 inhibitor with potent PARP-trapping activity, inducing synthetic lethality in BRCA-deficient tumor cells by preventing DNA damage repair [2].
⚠️ Safety Snapshot
| Safety Category | Talazoparib (n=286) | Standard Therapy (n=126) |
|---|---|---|
| Hematologic AEs, grade 3–4 | 55% | 38% |
| Nonhematologic AEs, grade 3 | 32% | 38% |
Key safety metrics:
- Treatment-related deaths: 1 (talazoparib: veno-occlusive disease) vs 1 (standard therapy: sepsis)
- Discontinuations due to AE: 5.9% vs 8.7%
- Dose modification (reduction/interruption): 66% vs 60%
- Serious AEs: 91 (31.8%) vs 37 (29.4%)
The primary safety concern is myelosuppression (anemia, neutropenia, thrombocytopenia). Hepatic toxicity was less common with talazoparib (9%) than chemotherapy (20%).
📊 Key Numbers
Median follow-up: 11.2 months
| Outcome | Talazoparib | Standard Therapy | HR/OR (95% CI) | p-value |
|---|---|---|---|---|
| PFS (BICR) | 8.6 mo | 5.6 mo | HR 0.54 (0.41–0.71) | P<0.001 |
| OS (interim, 57% events) | 22.3 mo | 19.5 mo | HR 0.76 (0.55–1.06) | P=0.11 |
| ORR (measurable disease) | 62.6% | 27.2% | OR 5.0 (2.9–8.8) | P<0.001 |
| CBR at 24 weeks | 68.6% | 36.1% | OR 4.3 (2.7–6.8) | P<0.001 |
| Duration of response | 5.4 mo | 3.1 mo | — | — |
PFS at 1 year: 37% vs 20%
Quality of life (EORTC QLQ-C30 GHS): Talazoparib +3.0 (improved) vs standard therapy −5.4 (worsened); P<0.001
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| EMBRACA | Talazoparib vs PC | gBRCA-mut, HER2-neg advanced BC, ≤3 prior chemo | PFS (BICR) | 8.6 vs 5.6 mo; HR 0.54 | [1] |
| OlympiAD | Olaparib vs PC | gBRCA-mut, HER2-neg mBC, ≤2 prior chemo | PFS | See [4] | [4] |
| OlympiA | Olaparib vs placebo (adjuvant) | gBRCA-mut, HER2-neg early BC, high risk | iDFS | See [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
BRCA1: HR 0.59 (95% CI 0.39–0.90) — benefit in both BRCA mutation types BRCA2: HR 0.47 (95% CI 0.32–0.70) — numerically greater benefit Triple-negative: HR 0.60 (95% CI 0.41–0.87) — consistent benefit HR-positive: HR 0.47 (95% CI 0.32–0.71) — consistent benefit CNS metastases — Yes: HR 0.32 (95% CI 0.15–0.68) — pronounced benefit (small subgroup) Prior platinum — Yes: HR 0.76 (95% CI 0.40–1.45) — attenuated benefit, CI crosses 1.0 Prior platinum — No: HR 0.52 (95% CI 0.39–0.71) — robust benefit
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Approved (Oct 2018) for gBRCA-mut, HER2-neg locally advanced/metastatic BC [2] |
| EMA | Approved for similar indications |
⚠️ Verify current regulatory status before prescribing.
NCCN: Preferred regimen for gBRCA1/2-mut, HER2-neg recurrent/metastatic BC (Category 1) [3]
Companion diagnostic: BRACAnalysis CDx (Myriad Genetics); other FDA-approved germline BRCA tests also acceptable [2]
⚡ Grey Zones
- OS not significant at interim analysis (P=0.11); confounded by 18% subsequent PARP inhibitor use in the control arm
- Prior platinum attenuates benefit — HR 0.76 (CI crosses 1.0) vs HR 0.52 in platinum-naïve; sequencing questions remain
- Optimal treatment duration undefined — continuous therapy until progression, with no data on duration-based stopping
- No head-to-head comparison between talazoparib and olaparib exists; choice based on toxicity profile and patient preference
- Combination strategies not addressed — monotherapy only; PARP + immunotherapy data in this population remain limited
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763. doi:10.1056/NEJMoa1802905
- Talzenna (talazoparib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533. doi:10.1056/NEJMoa1706450
- Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394-2405. doi:10.1056/NEJMoa2105215